Page last updated: 2024-09-02

tadalafil and vardenafil

tadalafil has been researched along with vardenafil in 13 studies

Compound Research Comparison

Studies
(tadalafil)
Trials
(tadalafil)
Recent Studies (post-2010)
(tadalafil)
Studies
(vardenafil)
Trials
(vardenafil)
Recent Studies (post-2010) (vardenafil)
1,7423921,08932020

Protein Interaction Comparison

ProteinTaxonomytadalafil (IC50)vardenafil (IC50)
cystic fibrosis transmembrane conductance regulatorHomo sapiens (human)0.14
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)1.7801
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaHomo sapiens (human)0.0077
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)1.6334
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.817
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)0.57
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaHomo sapiens (human)0.0077
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)0.0077
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)4.15
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaHomo sapiens (human)0.0077
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)0.0077
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)0.265
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)1.3846
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)2.091
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)4.15
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)2.091
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)1.5801
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)1.9
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)0.0077
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)0.265
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)1.34
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)1.3701
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)1.6601
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)1.4883

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (46.15)29.6817
2010's7 (53.85)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adam, L; Beyer, B; Chong, S; Ferrer, P; He, B; Henwood, A; Humphrey, WG; Krupinski, J; Macor, JE; Mason, H; Normandin, D; Pongrac, R; Seliger, L; Wang, J; Wu, X; Yu, G; Zhang, R1
Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY1
Asberom, T; Boyle, CD; Chackalamannil, S; Chintala, M; Clader, JW; Greenlee, WJ; Guzik, H; Hu, Y; Hu, Z; Kurowski, S; Lankin, CM; Myers, J; Palamanda, J; Pissarnitski, DA; Skell, J; Stamford, AW; Vemulapalli, S; Wang, P; Wang, Y; Wu, P; Xu, R1
Hughes, RA; Manallack, DT; Thompson, PE1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Antunes, JE; da Cunha, EF; Freitas, MP; Ramalho, TC; Rittner, R1
Arancio, O; Deng, SX; Feng, Y; Fiorito, J; Francis, YI; Landry, DW; Rao, S; Saeed, F; Staniszewski, A; Thakkar, DM; Zhang, H1
Fujishige, K; Hikota, M; Kikkawa, K; Koga, Y; Kotera, J; Matsuki, K; Morimoto, H; Murakami, M; Omori, K; Sakamoto, T; Yamada, K1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cuadrado-Tejedor, M; de Miguel, I; Espelosin, M; Estella-Hermoso de Mendoza, A; García-Barroso, C; Garcia-Osta, A; Haizhong, T; Musheng, X; Oyarzabal, J; Pérez-González, M; Rabal, O; Sáez, E; Sánchez-Arias, JA; Ugarte, A; Ursua, S; Wei, W2
Leeson, PD; Young, RJ1
Cheng, C; Jiang, Y; Lou, H; Qiao, Y; Sun, B; Tan, J; Wu, Y; Xie, Z; Zhao, S; Zheng, H1

Reviews

3 review(s) available for tadalafil and vardenafil

ArticleYear
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
    Journal of medicinal chemistry, 2005, May-19, Volume: 48, Issue:10

    Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines

2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
    Journal of medicinal chemistry, 2018, 08-09, Volume: 61, Issue:15

    Topics: Animals; Chemical Phenomena; Drug Discovery; Humans; Hydrophobic and Hydrophilic Interactions

2018

Other Studies

10 other study(ies) available for tadalafil and vardenafil

ArticleYear
Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
    Journal of medicinal chemistry, 2003, Feb-13, Volume: 46, Issue:4

    Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Animals; Biological Availability; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Enzyme Inhibitors; Erectile Dysfunction; Female; Male; Penis; Pyridazines; Rabbits; Rats; Structure-Activity Relationship

2003
Structural basis for the activity of drugs that inhibit phosphodiesterases.
    Structure (London, England : 1993), 2004, Volume: 12, Issue:12

    Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary

2004
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Bioorganic & medicinal chemistry letters, 2005, May-02, Volume: 15, Issue:9

    Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Models, Molecular; Molecular Structure; Phosphodiesterase I; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Rats; Sildenafil Citrate; Structure-Activity Relationship; Sulfones; Vasodilator Agents

2005
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
    Bioorganic & medicinal chemistry, 2008, Aug-15, Volume: 16, Issue:16

    Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Quantitative Structure-Activity Relationship; Rats; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride

2008
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2013, Volume: 60

    Topics: Alzheimer Disease; Animals; Disease Models, Animal; Drug Discovery; Female; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Phosphodiesterase 5 Inhibitors; Quinolines

2013
The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.
    Bioorganic & medicinal chemistry letters, 2014, Dec-01, Volume: 24, Issue:23

    Topics: Animals; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rabbits

2014
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
    Journal of medicinal chemistry, 2016, 10-13, Volume: 59, Issue:19

    Topics: Acetylation; Alzheimer Disease; Animals; Cell Line; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors

2016
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2018, Apr-25, Volume: 150

    Topics: Alzheimer Disease; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Design; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Molecular Structure; Neuroglia; Phosphodiesterase 5 Inhibitors; Structure-Activity Relationship

2018
Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.
    European journal of medicinal chemistry, 2018, Oct-05, Volume: 158

    Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Humans; Male; Mesenteric Arteries; Molecular Docking Simulation; Phosphodiesterase 5 Inhibitors; Rats, Wistar; Structure-Activity Relationship; Vasodilator Agents

2018